Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III studyRobert L. Ferris, Lisa Licitra, Tudor–Eliade Ciuleanu et al.|Annals of Oncology|2020Cited by 365
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III studyAmanda Psyrri, Tanguy Y. Seiwert, Jérôme Fayette et al.|Annals of Oncology|2022Cited by 144
Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker TestingAntonio López-Beltrán, Markus Eckstein, Fernando López‐Ríos et al.|Cancers|2021Cited by 34
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaSophie Wildsmith, Ricard Mesı́a, Weimin Li et al.|Clinical Cancer Research|2023Cited by 30